Abiraterone Lowers Risk of Death from Prostate Cancer in Two Clinical Trials
June 6th 2017According to findings presented at the 2017 ASCO Annual Meeting, earlier intervention with abiraterone acetate (Zytiga) lowered the risk of death by 40% for men with high-risk advanced or metastatic prostate cancer.
Pregnancy After Early-Stage Breast Cancer Does Not Increase Recurrence Risk
June 6th 2017A recent study presented at the 2017 ASCO Annual Meeting found that breast cancer survivors who became pregnant had no greater risk of recurrence or death than women who underwent breast cancer treatment but did not become pregnant.
Abemaciclib Plus Fulvestrant Reduces Breast Cancer Progression in Phase III Trial
June 5th 2017As presented at the 2017 ASCO Annual Meeting, adding abemaciclib to fulvestrant can reduce the risk of disease progression or death by 45% compared to fulvestrant alone in pretreated patients with HR+/HER2-negative breast cancer.
Shorter Adjuvant Chemo in Colon Cancer Is Effective, Reduces Neuropathy Risk
June 5th 2017According to findings presented at the 2017 ASCO Annual Meeting, patients with low-risk advanced colon cancer would benefit from a reduction in chemotherapy post-surgery, without increasing risk of recurrence, to reduce risk of neuropathy.
Understanding Breast Implant-Associated Anaplastic Large Cell Lymphoma
May 31st 2017A form of T-cell (non-Hodgkin) lymphoma known as breast implant associated anaplastic large-cell lymphoma (BIA-ALCL) has been noted as a rare association with the implant-based approach of reconstructive surgery post mastectomy.
More Stage I Cancers Diagnosed After ACA
May 19th 2017More Stage I cancers were diagnosed after the passage of the Affordable Care Act (ACA), also known as Obamacare, within five screenable disease types: colorectal cancer, female breast cancer, cervical cancer, lung cancer, and prostate cancer).